Pre-clinical Characterization of Orally Bioavailable CNS-Penetrant Degraders for the Treatment of Multiple Sclerosis
Time: 1:15 pm
day: Conference Day 2
Details:
- Selectivity Profiling: Assessing the specificity of the degrader candidate across a range of targets
- Target Engagement Assays: Measuring the binding and interaction of the degrader candidate with its intended target
